FDA warns Bioactive Services/Herstat that Herstat GST is an unapproved new drug for genital sores.
What happened
FDA reviewed the websites drsosnowski.com and herstat.com in July 2026, plus Facebook and Instagram accounts that direct consumers to the website to buy products. FDA found Herstat GST labeled and promoted as a treatment for genital sores and symptoms including pain, itching, and inflammation. FDA determined it is an unapproved new drug and does not conform to the applicable OTC external analgesic monograph.
What FDA found
Website and label claims that Herstat GST treats genital sores and symptoms make it a drug.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)Herstat GST is a new drug because it is not generally recognized as safe and effective for its labeled uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)No FDA-approved application is in effect for Herstat GST, so selling it is marketing an unapproved new drug.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)The genital sore claims go beyond the permitted OTC external analgesic indications, so the product does not qualify under OTC monograph M017 or section 505G.
FD&C Act section 505G; OTC Monograph M017
What FDA wants
Send a written response within 15 business days to FDAAdvisory@fda.hhs.gov, including corrective steps, steps to prevent recurrence, and related documentation, with reference number 734784 in the subject line.
Who should pay attention
- retailers and online marketplaces selling Herstat GST
- companies marketing OTC topical products with disease-treatment claims
- consumers who use genital sore or STI symptom products instead of medical care
This is a summary. Read the original letter on fda.gov.